In the UK a cannabis based medical extract, nabiximols (see box 1) 4 has been approved for "symptom improvement in patients with moderate to severe spasticity due to multiple sclerosis who have not responded adequately to other anti-spasticity medication and who demonstrate clinically significant improvement in spasticity related symptoms during an initial trial of therapy.on a named patient basis."
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Should doctors consider prescribing cannabinoids for this indication? Should they consider prescribing nabiximols off label for other chronic conditions? What should doctors do if their patients disclose that they are smoking cannabis for medical purposes?
What is the evidence of uncertainty?
To examine the effectiveness and safety of medicinal use of cannabinoids we searched the Cochrane Central
Register of Controlled Trials (CENTRAL), Medline, and Embase without language restriction for studies published from 1 January 2008 to 3 October 2013. We checked references of reviews and included trials to identify additional studies. We considered indications for which cannabinoids have received regulatory approval in one or more countries (box 2), as well as use in chronic pain-the most common reported medical reason for use in the US. 6 We used the Cochrane search strategy to identify systematic reviews and randomised controlled trials and included terms for cannabinoids and chronic neuropathic, chronic cancer pain, and non-cancer pain.
Antiemetic and appetite stimulating effects
In the 1970s and 1980s clinical trials compared the antiemetic effects of THC with a placebo or prochlorperazine, the drug then used to treat nausea in patients with cancer. 1 7 These studies found that cannabinoids were more effective than placebo or prochlorperazine. However, the small size of most of the studies made it difficult to draw firm conclusions.
8 9
There are now newer, much more effective, antinausea drugs, such as ondansetron. treatment of muscle spasticity in multiple sclerosis, its efficacy and tolerability were poorly documented, and that further data were needed on its long term safety.
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An additional high quality randomised controlled trial (n=339), not included in this review, reported no significant difference in the proportion who responded (≥30% improvement in pain) between those receiving nabiximols (50%) versus placebo (45%). In a subsequent randomised withdrawal phase that involved 58 participants, there were more treatment failures among those in the placebo group (57% v24%). 22 Although a recent small crossover trial (n=37) reported significantly greater improvement in spasticity and pain with cannabis versus placebo cigarettes, self selection bias (many participants had previously used cannabis) and unblinding of participants makes it impossible to draw firm conclusions.
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Thus, the effectiveness of cannabinoids for the treatment of muscle spasticity or neuropathic pain in multiple sclerosis is unclear and any benefit is likely to be modest, while mild to moderate adverse events are common and long term safety has not been established.
Effects on other neuropathic pain
Systematic reviews of trials of cannabinoids in participants with other types of neuropathic pain have reported mixed results. For example, in a 2011 high quality systematic review that reported results qualitatively, seven of nine trials of people with other types of chronic neuropathic pain reported significantly greater analgesic effects for cannabinoids versus placebo, although the effect sizes were modest and trials were of short duration.
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A recent systematic review of drugs for neuropathic pain associated with spinal cord injury included one small (n=7) crossover trial that reported comparable benefits from dronabinol and diphenhydramine, an antihistamine that does not have pain relief properties but mimics some of the possible side effects of dronabinol. 24 25 A systematic review of pharmacological treatment of HIV associated neuropathy that pooled data from two small placebo controlled trials of smoked cannabis reported a relative risk of at least a 30% improvement in pain of 2.38 (1.38 to 4.10) in favour of smoked cannabis. 26 Both trials, however, were at high risk of performance and detection bias, and one trial reported more adverse effects in the cannabis group, including two withdrawals (one for cannabis induced psychosis and intractable smoking related cough). One small (n=30) placebo controlled trial in people with painful diabetic neuropathy found that nabiximols did not reduce pain. 27 Another small trial (n=37) of nabilone, a synthetic cannabinoid, in refractory diabetic neuropathic pain, found a significant benefit compared with placebo in 70% of participants (26/37), who were deemed to be responders (achieved ≥30% improvement in pain) to nabilone in an initial single arm blinded phase.
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The effectiveness of cannabinoids for the treatment of other neuropathic pain has not been proved.
Effects on other chronic pain
One small low quality trial of nabiximols was included in a Cochrane review of neuromodulators for rheumatoid arthritis. 29 This trial reported a small significant benefit over placebo in pain-on a scale of 0-5, the mean between group difference was −0.72 (−1.31 to −0.13). Participants in the cannabinoid group were significantly more likely to experience an adverse event (mostly dizziness, dry mouth, and light headedness; number needed to harm 3, 3 to 13).
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A recent systematic review of medicinal plants or related natural products for fibromyalgia identified two small trials of the efficacy of nabilone that were judged to be at low risk of bias. 30 One trial found a significantly greater reduction in pain and anxiety with nabilone than with placebo. 31 A second trial in people with fibromyalgia and chronic insomnia reported that nabilone and amitriptyline had similar effects on pain but that nabilone caused more adverse effects, particularly drowsiness and dizziness.
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A crossover trial reported that nabilone reduced pain more than ibuprofen in people with medication overuse headache, although the between group difference was small and unlikely to be of clinical importance.
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Thus, the effectiveness of cannabinoids in treating other chronic pain is unclear and any benefit is likely to be modest. Mild to moderate adverse events are often reported and long term safety has not been established.
Effects on cancer pain
A systematic review including 18 placebo controlled trials of cannabinoids for chronic cancer and non-cancer pain reported a clinically significant greater reduction in pain with cannabinoids from a pooled (fixed model) analysis that included four cancer trials and three trials for other chronic pain (standardised mean difference −0.61 (−0.37 to 0.84)). 34 However, the authors outlined serious sources of bias in the included trials that may have favoured the actively treated groups, including selection and attrition bias and perhaps inadequacy of participant blinding. The review also found that cannabinoids were more likely than placebo to be associated with adverse events linked to alterations in perception (odds ratio 4.51, 3.0 to 6.66; 10 trials), motor function (3.93, 2.83 to 5.47; 10 trials), and cognitive function (4.46, 2.37 to 8.27; five trials).
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Two additional trials of cannabinoids for people with cancer and an inadequate response to opioids, published after this review, also reported favourable efficacy results. However, in one trial higher doses of nabiximols (11-16 sprays/day), but not low (1-4 sprays/day) or medium doses (6-10 sprays/day), produced significantly more adverse events than placebo. 35 In the other trial, THC and cannabidiol worsened nausea and vomiting compared with placebo.
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Thus, the effectiveness of cannabinoids for the treatment of chronic cancer pain remains unclear, although any benefit is likely to be modest. The available evidence indicates a risk of potentially serious adverse effects, including alterations in perception, motor function, and cognitive function.
Chronic adverse events
Box 3 outlines adverse effects of chronic recreational cannabis smoking identified from epidemiological studies. If a patient requests nabiximols for a non-approved or off-label indication, clinicians should avoid taking this medicolegal responsibility. If first line treatments have been ineffective or the patient insists on nabiximols, it may be sensible, when available, to refer the patient for specialist management of the condition, where a trial of cannabinoids might be undertaken.
Doctors are not legally able to prescribe cannabis (the plant product that is smoked) in any jurisdiction because it has not received regulatory approval (although doctors may "recommend" its use in some US states). Many doctors will be faced with patients using cannabis for complex symptoms of multiple chronic disabling conditions for which there are limited treatment options. Doctors should discuss, in a dispassionate and non-judgmental and supportive manner, the advisability or otherwise of using cannabis to palliate such symptoms. There is no clear evidence for effectiveness in treating pain, any benefits are likely to be modest, and there is no clear evidence that putative benefits outweigh possible harms.
When symptoms of cannabis dependence are elicited it is appropriate to discuss the wisdom of continued use in the context of the illness and the prognosis, and, if appropriate, to offer the patient support for withdrawal.
Helping patients who wish to use cannabis for symptomatic relief to live as comfortably and productively as possible is an important and valuable goal of palliative and rehabilitation treatment.
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